Posted by Michael Wonder on 01 May 2026
Ray Therapeutics granted Priority Medicines (PRIME) designation from the EMA for RTx-015 in retinitis pigmentosa
29 April 2026 - PRIME designation follows recent FDA regenerative medicine advanced therapy designation, continues regulatory momentum for RTx-015.
Ray Therapeutics today announced that the EMA has granted Priority Medicines (PRIME) designation to its lead program, RTx-015, for the treatment of retinitis pigmentosa.
